Mechanistically, the ADSCs-activated TGF-β1/SMAD3 signaling pathway transcriptionally upregulates the expression of ANGPTL4, which endows tumor cells with an invasive phenotype and is associated with a poor prognosis in CRC patients. This evidence concerns the gene SMAD3 and neoplasm.